Morihiro Higashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Morihiro Higashi has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Jun-Ichi Tamaru
Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
4 shared publications Masahiro Kizaki
Department of Hematology, Saitama Medical Center Saitama Medical University Kawagoe Japan
3 shared publications- Shuji Momose
Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
3 shared publications - Shunya Hanakita
Department of Neurosurgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan
3 shared publications Chiaki Murakami
Department of Pathology, Saitama Medical University, Saitama Medical Center, Kawagoe, Saitama, Japan
2 shared publicationsJun-Ichi Tamaru
Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
2 shared publications
Latest Publications
- 13 July 2026
- Published by Wiley in Histopathology
- Vol. 89 (5) , 901-905
Malignant struma ovarii: advances in molecular pathogenesis, classification, diagnosis and treatment
- 13 July 2026
- Published by Wiley in Histopathology
- Vol. 89 (5) , 901-905
Malignant struma ovarii: advances in molecular pathogenesis, classification, diagnosis and treatment
- Open Access
Metabolic and Molecular Mechanisms of Gemcitabine Resistance in Urothelial Carcinoma
Gemcitabine-based chemotherapy has long served as a standard treatment for urothelial carcinoma (UC), particularly in perioperative and metastatic settings. However, therapeutic efficacy is frequently limited by intrinsic or acquired resistance. Gemcitabine functions as a prodrug whose activity depends on coordinated processes involving cellular uptake, intracellular activation, metabolic inactivation, and nucleotide metabolism. Increasing evidence suggests that resistance in UC is mediated by multiple interconnected mechanisms beyond alterations in gemcitabine transport, activation, and inactivation alone. Key molecular determinants include human equilibrative nucleoside transporter 1 (hENT1), deoxycytidine kinase (dCK), cytidine deaminase (CDA), and ribonucleotide reductase regulatory subunit M1 (RRM1), which is involved in nucleotide pool maintenance and DNA synthesis. In addition, replication stress responses, apoptosis evasion pathways, and tumor microenvironment-associated factors also contribute to gemcitabine resistance. Stress-adaptive pathways involving Y-box binding protein 1 (YB-1), hypoxia-inducible factor-1 alpha (HIF-1α), and autophagy-related mechanisms may further promote survival under chemotherapy-induced stress conditions. In addition, extracellular mucin-associated mechanisms may alter intratumoral drug accessibility and contribute to resistance. In this review, we summarize UC-specific evidence regarding gemcitabine resistance and discuss how these pathways collectively shape an integrated resistant phenotype.
Open AccessMetabolic and Molecular Mechanisms of Gemcitabine Resistance in Urothelial Carcinoma
Gemcitabine-based chemotherapy has long served as a standard treatment for urothelial carcinoma (UC), particularly in perioperative and metastatic settings. However, therapeutic efficacy is frequently limited by intrinsic or acquired resistance. Gemcitabine functions as a prodrug whose activity depends on coordinated processes involving cellular uptake, intracellular activation, metabolic inactivation, and nucleotide metabolism. Increasing evidence suggests that resistance in UC is mediated by multiple interconnected mechanisms beyond alterations in gemcitabine transport, activation, and inactivation alone. Key molecular determinants include human equilibrative nucleoside transporter 1 (hENT1), deoxycytidine kinase (dCK), cytidine deaminase (CDA), and ribonucleotide reductase regulatory subunit M1 (RRM1), which is involved in nucleotide pool maintenance and DNA synthesis. In addition, replication stress responses, apoptosis evasion pathways, and tumor microenvironment-associated factors also contribute to gemcitabine resistance. Stress-adaptive pathways involving Y-box binding protein 1 (YB-1), hypoxia-inducible factor-1 alpha (HIF-1α), and autophagy-related mechanisms may further promote survival under chemotherapy-induced stress conditions. In addition, extracellular mucin-associated mechanisms may alter intratumoral drug accessibility and contribute to resistance. In this review, we summarize UC-specific evidence regarding gemcitabine resistance and discuss how these pathways collectively shape an integrated resistant phenotype.
- Open Access
- 8 May 2026
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 17, 267
18 F-fluciclovine positron emission tomography uptake is not exclusive to malignant brain tumors: Two cases of low-grade and benign lesions with detailed pathological findings
Background: 18 F-fluciclovine ( 18 F-FACBC) positron emission tomography (PET) is used to visualize malignant brain tumors as part of preoperative surgical planning. We previously reported that the degree of 18 F-FACBC uptake correlated with tumor malignancy; however, data on low-grade and benign brain lesions remain limited. We report two cases of nonmalignant brain lesions with apparent 18 F-FACBC uptake. Case Description: Both cases were suspected to be high-grade gliomas based on preoperative magnetic resonance imaging (MRI) and 18 F-FACBC PET findings, with positive intraoperative 5-aminolevulinic acid fluorescence. Despite these findings, postoperative histopathology revealed pilocytic astrocytoma (World Health Organization grade 1) and capillary hemangioma, respectively. These cases demonstrate that high 18 F-FACBC uptake does not necessarily indicate a high-grade or malignant brain tumor. To further evaluate 18 F-FACBC accumulation, we analyzed lesion-to-normal (L/N) tissue ratios in these cases and our previously reported series, finding higher L/N ratios in high-grade tumors (mean L/N ratio: high-grade vs. low-grade = 8.40 vs. 3.16). Conclusion: Although existing data on the behavior of 18 F-FACBC PET in low-grade and benign lesions are scarce, our cases provide valuable insight into its behavior in these lesions through intraoperative and pathological findings. At the same time, our findings highlight that interpretation of 18 F-FACBC PET should not rely solely on visual assessment and underscore the importance of incorporating quantitative parameters such as the L/N ratio for objective evaluation. Although the clinical application of 18 F-FACBC PET in brain tumors remains limited, further accumulation of clinical data is warranted to establish optimal evaluation strategies and its clinical role in neuro-oncological practice.
- 8 May 2026
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 17, 267
Open Access18 F-fluciclovine positron emission tomography uptake is not exclusive to malignant brain tumors: Two cases of low-grade and benign lesions with detailed pathological findings
Background: 18 F-fluciclovine ( 18 F-FACBC) positron emission tomography (PET) is used to visualize malignant brain tumors as part of preoperative surgical planning. We previously reported that the degree of 18 F-FACBC uptake correlated with tumor malignancy; however, data on low-grade and benign brain lesions remain limited. We report two cases of nonmalignant brain lesions with apparent 18 F-FACBC uptake. Case Description: Both cases were suspected to be high-grade gliomas based on preoperative magnetic resonance imaging (MRI) and 18 F-FACBC PET findings, with positive intraoperative 5-aminolevulinic acid fluorescence. Despite these findings, postoperative histopathology revealed pilocytic astrocytoma (World Health Organization grade 1) and capillary hemangioma, respectively. These cases demonstrate that high 18 F-FACBC uptake does not necessarily indicate a high-grade or malignant brain tumor. To further evaluate 18 F-FACBC accumulation, we analyzed lesion-to-normal (L/N) tissue ratios in these cases and our previously reported series, finding higher L/N ratios in high-grade tumors (mean L/N ratio: high-grade vs. low-grade = 8.40 vs. 3.16). Conclusion: Although existing data on the behavior of 18 F-FACBC PET in low-grade and benign lesions are scarce, our cases provide valuable insight into its behavior in these lesions through intraoperative and pathological findings. At the same time, our findings highlight that interpretation of 18 F-FACBC PET should not rely solely on visual assessment and underscore the importance of incorporating quantitative parameters such as the L/N ratio for objective evaluation. Although the clinical application of 18 F-FACBC PET in brain tumors remains limited, further accumulation of clinical data is warranted to establish optimal evaluation strategies and its clinical role in neuro-oncological practice.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Radiology
- Vol. 2026 (1) , 7322838
Hypoglycemic Encephalopathy Caused by Insulinoma With Reversible High Signals in the White Matter on Diffusion‐Weighted MRI: A Case Report
Hypoglycemic encephalopathy can result in reversible, and sometimes irreversible, lesions within the brain that need prompt recognition and treatment. The disease is relatively uncommon, but radiologists must keep in mind the rare radiologic findings of this disease. Although the most common cause is insulin, insulinoma is a rare etiology, and hypoglycemia is often misdiagnosed as epilepsy. A 66‐year‐old man presented with recurrent involuntary movements and impaired consciousness with neuropsychiatric symptoms without a history of antidiabetic therapy. Initial blood glucose was critically low at 29 mg/dL. Diffusion‐weighted imaging (DWI) revealed reversible high signals in the white matter, involving the bilateral posterior limbs of the internal capsule, corona radiata, cerebral peduncle, and splenium of the corpus callosum. A fasting test and contrast‐enhanced computed tomography confirmed the diagnosis of insulinoma. Intravenous glucose was administered immediately, resulting in rapid clinical improvement. Laparoscopic distal pancreatectomy was subsequently performed. Clinical symptoms resolved completely within 1 day of glucose administration. Follow‐up DWI performed 2 months after onset demonstrated complete resolution of all white matter hyperintensities without recurrence. The patient reported feeling well without recurrence of the symptoms. We report a case of hypoglycemic encephalopathy caused by insulinoma with reversible high signals in the white matter on DWI, presenting with neuropsychiatric symptoms mimicking epilepsy. We also discuss findings of magnetic resonance imaging in hypoglycemic encephalopathy with emphasis on the time course of the findings.
- 1 January 2026
- Published by Wiley in Case Reports in Radiology
- Vol. 2026 (1) , 7322838
Open AccessHypoglycemic Encephalopathy Caused by Insulinoma With Reversible High Signals in the White Matter on Diffusion‐Weighted MRI: A Case Report
Hypoglycemic encephalopathy can result in reversible, and sometimes irreversible, lesions within the brain that need prompt recognition and treatment. The disease is relatively uncommon, but radiologists must keep in mind the rare radiologic findings of this disease. Although the most common cause is insulin, insulinoma is a rare etiology, and hypoglycemia is often misdiagnosed as epilepsy. A 66‐year‐old man presented with recurrent involuntary movements and impaired consciousness with neuropsychiatric symptoms without a history of antidiabetic therapy. Initial blood glucose was critically low at 29 mg/dL. Diffusion‐weighted imaging (DWI) revealed reversible high signals in the white matter, involving the bilateral posterior limbs of the internal capsule, corona radiata, cerebral peduncle, and splenium of the corpus callosum. A fasting test and contrast‐enhanced computed tomography confirmed the diagnosis of insulinoma. Intravenous glucose was administered immediately, resulting in rapid clinical improvement. Laparoscopic distal pancreatectomy was subsequently performed. Clinical symptoms resolved completely within 1 day of glucose administration. Follow‐up DWI performed 2 months after onset demonstrated complete resolution of all white matter hyperintensities without recurrence. The patient reported feeling well without recurrence of the symptoms. We report a case of hypoglycemic encephalopathy caused by insulinoma with reversible high signals in the white matter on DWI, presenting with neuropsychiatric symptoms mimicking epilepsy. We also discuss findings of magnetic resonance imaging in hypoglycemic encephalopathy with emphasis on the time course of the findings.
- 18 December 2025
- Published by Wiley in Pathology International
- Vol. 76 (1)
Significance and Utility of Immunohistochemical MTAP Expression to Predict CDKN2A Genomic Status in Diffuse Large B‐Cell Lymphoma
Recent genomic studies have delineated genetic subtypes of diffuse large B‐cell lymphoma (DLBCL), and CDKN2A deletion has been reported as an adverse prognostic factor across several of these subtypes. Because MTAP , located adjacent to CDKN2A on 9p21, is frequently co‐deleted, loss of MTAP protein expression may serve as a surrogate marker for CDKN2A homozygous deletion (HD) in a subset of malignancies. However, large cohort studies linking MTAP immunohistochemistry (IHC) with CDKN2A genomic status by fluorescence in situ hybridization (FISH) and/or next‐generation sequencing (NGS) have been lacking. We therefore investigated the diagnostic significance of MTAP and p16 expression by IHC in relation to the genomic status of CDKN2A and MTAP (by FISH and NGS) in 238 DLBCL cases. Loss of MTAP expression was observed in 40 cases, of which 37 (92.5%) also showed concomitant loss of p16 expression. Among these 37 cases, 32 were identified as having CDKN2A HD by combined FISH/NGS analysis, whereas only 22 were detected by FISH alone. These findings indicate that loss of MTAP expression serves as a surrogate marker for CDKN2A HD, and that MTAP IHC is preferable to FISH for screening CDKN2A HD in DLBCL.
- 18 December 2025
- Published by Wiley in Pathology International
- Vol. 76 (1)
Significance and Utility of Immunohistochemical MTAP Expression to Predict CDKN2A Genomic Status in Diffuse Large B‐Cell Lymphoma
Recent genomic studies have delineated genetic subtypes of diffuse large B‐cell lymphoma (DLBCL), and CDKN2A deletion has been reported as an adverse prognostic factor across several of these subtypes. Because MTAP , located adjacent to CDKN2A on 9p21, is frequently co‐deleted, loss of MTAP protein expression may serve as a surrogate marker for CDKN2A homozygous deletion (HD) in a subset of malignancies. However, large cohort studies linking MTAP immunohistochemistry (IHC) with CDKN2A genomic status by fluorescence in situ hybridization (FISH) and/or next‐generation sequencing (NGS) have been lacking. We therefore investigated the diagnostic significance of MTAP and p16 expression by IHC in relation to the genomic status of CDKN2A and MTAP (by FISH and NGS) in 238 DLBCL cases. Loss of MTAP expression was observed in 40 cases, of which 37 (92.5%) also showed concomitant loss of p16 expression. Among these 37 cases, 32 were identified as having CDKN2A HD by combined FISH/NGS analysis, whereas only 22 were detected by FISH alone. These findings indicate that loss of MTAP expression serves as a surrogate marker for CDKN2A HD, and that MTAP IHC is preferable to FISH for screening CDKN2A HD in DLBCL.
- Open Access
- 24 November 2025
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 10 (21)
18F-Fluciclovine PET enables accurate and safe resection of malignant brain tumors: illustrative cases
BACKGROUND: In malignant brain tumor surgery, maximal safe resection is essential to lower recurrence while minimizing complications. However, accurate preoperative assessment of tumor infiltration remains difficult and an unmet need. 18 F-Fluciclovine ( 18 F-FACBC) PET, an innovative molecular imaging technique, has recently emerged as a preoperative tool. The authors present cases highlighting its clinical utility. OBSERVATIONS: The authors report on the cases of 3 brain tumor patients: a 54-year-old female with glioblastoma, a 17-year-old male with recurrent teratoma, and a 24-year-old female with inflammatory myofibroblastic tumor. In all cases, preoperative 18 F-FACBC PET was performed, gross-total resection was achieved, and no patient developed permanent neurological deficits. In a representative case, 18 F-FACBC identified a tumor-infiltrated region not visualized on contrast-enhanced MRI and indistinguishable from normal brain during surgery; this region was resected and later histopathologically confirmed as tumor tissue. Without PET, it would likely have remained unresected. Surprisingly, molecular analysis suggested that 18 F-FACBC accumulated mainly not in tumor cells but in infiltrating immune cells, contributing to the imaging signal. LESSONS: 18 F-FACBC PET can aid in the accurate resection of malignant brain tumors and improve outcomes. Yet, the mechanisms of uptake and visualization remain unclear. Larger cohort studies are needed to confirm the long-term efficacy of this promising imaging tool. https://thejns.org/doi/10.3171/CASE25707
- 24 November 2025
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 10 (21)
Open Access18F-Fluciclovine PET enables accurate and safe resection of malignant brain tumors: illustrative cases
BACKGROUND: In malignant brain tumor surgery, maximal safe resection is essential to lower recurrence while minimizing complications. However, accurate preoperative assessment of tumor infiltration remains difficult and an unmet need. 18 F-Fluciclovine ( 18 F-FACBC) PET, an innovative molecular imaging technique, has recently emerged as a preoperative tool. The authors present cases highlighting its clinical utility. OBSERVATIONS: The authors report on the cases of 3 brain tumor patients: a 54-year-old female with glioblastoma, a 17-year-old male with recurrent teratoma, and a 24-year-old female with inflammatory myofibroblastic tumor. In all cases, preoperative 18 F-FACBC PET was performed, gross-total resection was achieved, and no patient developed permanent neurological deficits. In a representative case, 18 F-FACBC identified a tumor-infiltrated region not visualized on contrast-enhanced MRI and indistinguishable from normal brain during surgery; this region was resected and later histopathologically confirmed as tumor tissue. Without PET, it would likely have remained unresected. Surprisingly, molecular analysis suggested that 18 F-FACBC accumulated mainly not in tumor cells but in infiltrating immune cells, contributing to the imaging signal. LESSONS: 18 F-FACBC PET can aid in the accurate resection of malignant brain tumors and improve outcomes. Yet, the mechanisms of uptake and visualization remain unclear. Larger cohort studies are needed to confirm the long-term efficacy of this promising imaging tool. https://thejns.org/doi/10.3171/CASE25707
- Open Access
- 7 July 2025
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 10 (1)
Rapid response to BRAF/MEK inhibitor therapy within 2 weeks for high-grade glioma with leptomeningeal metastasis: illustrative case
BACKGROUND: High-grade gliomas, particularly isocitrate dehydrogenase–wildtype glioblastomas (GBMs), are highly aggressive brain tumors with limited treatment options and poor outcomes. A subset of these tumors, including epithelioid GBM, can harbor the BRAF V600E mutation, which drives tumor growth via persistent activation of the RAS/MAPK signaling pathway. Recently, the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) has been approved for treating inoperable solid tumors with this mutation. OBSERVATIONS: The authors present the case of a 51-year-old man with epithelioid GBM harboring the BRAF V600E mutation who developed early leptomeningeal metastasis (LMM) following standard therapy with surgery, temozolomide, and radiotherapy. Owing to disease progression, he was treated with dabrafenib and trametinib. Remarkably, the patient showed rapid clinical and radiographic improvement within 2 weeks of treatment initiation. MR images demonstrated significant reduction in tumor-associated edema and contrast enhancement. At the 28-week follow-up, the patient achieved near-complete radiographic remission without notable adverse effects. LESSONS: This case highlights the potential of BRAF/MEK inhibitor therapy to significantly improve outcomes in patients with aggressive gliomas and LMM, conditions typically associated with extremely poor prognosis. Further studies are needed to validate the long-term efficacy and safety of this targeted therapeutic approach in similar cases. https://thejns.org/doi/10.3171/CASE25247
- 7 July 2025
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 10 (1)
Open AccessRapid response to BRAF/MEK inhibitor therapy within 2 weeks for high-grade glioma with leptomeningeal metastasis: illustrative case
BACKGROUND: High-grade gliomas, particularly isocitrate dehydrogenase–wildtype glioblastomas (GBMs), are highly aggressive brain tumors with limited treatment options and poor outcomes. A subset of these tumors, including epithelioid GBM, can harbor the BRAF V600E mutation, which drives tumor growth via persistent activation of the RAS/MAPK signaling pathway. Recently, the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) has been approved for treating inoperable solid tumors with this mutation. OBSERVATIONS: The authors present the case of a 51-year-old man with epithelioid GBM harboring the BRAF V600E mutation who developed early leptomeningeal metastasis (LMM) following standard therapy with surgery, temozolomide, and radiotherapy. Owing to disease progression, he was treated with dabrafenib and trametinib. Remarkably, the patient showed rapid clinical and radiographic improvement within 2 weeks of treatment initiation. MR images demonstrated significant reduction in tumor-associated edema and contrast enhancement. At the 28-week follow-up, the patient achieved near-complete radiographic remission without notable adverse effects. LESSONS: This case highlights the potential of BRAF/MEK inhibitor therapy to significantly improve outcomes in patients with aggressive gliomas and LMM, conditions typically associated with extremely poor prognosis. Further studies are needed to validate the long-term efficacy and safety of this targeted therapeutic approach in similar cases. https://thejns.org/doi/10.3171/CASE25247
- Open Access
- 26 September 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 8 (10) , ytae536
Intimal metastasis of undifferentiated pleomorphic sarcoma on the right chest wall mimicking an aortic embolus
An 86-year-old man visited our hospital with right abdominal pain for 2 weeks. Contrast-enhanced computed tomography revealed a non-enhancing structure spanning > 55 mm in the thoracic descending aorta between the seventh and ninth thoracic vertebral levels (Panel A). Additionally, a heterogeneously enhanced mass (diameter, 65 mm) was observed on the right chest wall involving the eighth and ninth ribs (Panel B, white arrow). The intra-aortic structure was hyperintense on T1-weighted magnetic resonance images, indicating a thrombus in the descending aorta (Panel C). Needle biopsy of the chest wall lesion suggested spindle-cell carcinoma. The patient succumbed to disease progression 1 month after the initial visit, and an autopsy was performed. The right chest wall tumour was diagnosed as undifferentiated pleomorphic sarcoma (UPS), previously known as malignant fibrous histiocytoma. Atherosclerosis affected the aorta, extending from the thorax to the abdomen. In the descending thoracic aorta, a yellowish-white soft lesion occupied the lumen for >90 mm (Panel D), consisting of tumour emboli of proliferating UPS cells and necrosis (Panels E; red arrow, the aortic wall; Panel F). The tumour lesions extended from the vascular intima that was affected by the atheroma, and the elastic fibres in the tunica media were ruptured or missing. Although intimal metastases in the aorta have rarely been reported, possibly due to the rapid blood flow, factors affecting intimal conditions, such as arteriosclerosis, may promote intimal attachment of malignant cells derived from other organs.
- 26 September 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 8 (10) , ytae536
Open AccessIntimal metastasis of undifferentiated pleomorphic sarcoma on the right chest wall mimicking an aortic embolus
An 86-year-old man visited our hospital with right abdominal pain for 2 weeks. Contrast-enhanced computed tomography revealed a non-enhancing structure spanning > 55 mm in the thoracic descending aorta between the seventh and ninth thoracic vertebral levels (Panel A). Additionally, a heterogeneously enhanced mass (diameter, 65 mm) was observed on the right chest wall involving the eighth and ninth ribs (Panel B, white arrow). The intra-aortic structure was hyperintense on T1-weighted magnetic resonance images, indicating a thrombus in the descending aorta (Panel C). Needle biopsy of the chest wall lesion suggested spindle-cell carcinoma. The patient succumbed to disease progression 1 month after the initial visit, and an autopsy was performed. The right chest wall tumour was diagnosed as undifferentiated pleomorphic sarcoma (UPS), previously known as malignant fibrous histiocytoma. Atherosclerosis affected the aorta, extending from the thorax to the abdomen. In the descending thoracic aorta, a yellowish-white soft lesion occupied the lumen for >90 mm (Panel D), consisting of tumour emboli of proliferating UPS cells and necrosis (Panels E; red arrow, the aortic wall; Panel F). The tumour lesions extended from the vascular intima that was affected by the atheroma, and the elastic fibres in the tunica media were ruptured or missing. Although intimal metastases in the aorta have rarely been reported, possibly due to the rapid blood flow, factors affecting intimal conditions, such as arteriosclerosis, may promote intimal attachment of malignant cells derived from other organs.
- Open Access
Copy Number Analysis of 9p24.1 in Classic Hodgkin Lymphoma Arising in Immune Deficiency/Dysregulation
A subset of patients with rheumatoid arthritis receiving methotrexate develop immune deficiencies and dysregulation-associated lymphoproliferative disorders. Patients with these disorders often exhibit spontaneous regression after MTX withdrawal; however, chemotherapeutic intervention is frequently required in patients with classic Hodgkin lymphoma arising in immune deficiency/dysregulation. In this study, we examined PD-L1 expression levels and 9p24.1 copy number alterations in 27 patients with classic Hodgkin lymphoma arising from immune deficiency/dysregulation. All patients demonstrated PD-L1 protein expression and harbored 9p24.1 copy number alterations on the tumor cells. When comparing clinicopathological data and associations with 9p24.1 copy number features, the copy gain group showed a significantly higher incidence of extranodal lesions and clinical stages than the amplification group. Notably, all cases in the amplification group had latency type II, while 6/8 (75%) in the copy gain group had latency type II, and 2/8 (25%) had latency type I. Thus, a subset of the copy-gain group demonstrated more extensive extranodal lesions and higher clinical stages. This finding speculates the presence of a genetically distinct subgroup within the group of patients who develop immune deficiencies and dysregulation-associated lymphoproliferative disorders, which may explain certain characteristic features.
Open AccessCopy Number Analysis of 9p24.1 in Classic Hodgkin Lymphoma Arising in Immune Deficiency/Dysregulation
A subset of patients with rheumatoid arthritis receiving methotrexate develop immune deficiencies and dysregulation-associated lymphoproliferative disorders. Patients with these disorders often exhibit spontaneous regression after MTX withdrawal; however, chemotherapeutic intervention is frequently required in patients with classic Hodgkin lymphoma arising in immune deficiency/dysregulation. In this study, we examined PD-L1 expression levels and 9p24.1 copy number alterations in 27 patients with classic Hodgkin lymphoma arising from immune deficiency/dysregulation. All patients demonstrated PD-L1 protein expression and harbored 9p24.1 copy number alterations on the tumor cells. When comparing clinicopathological data and associations with 9p24.1 copy number features, the copy gain group showed a significantly higher incidence of extranodal lesions and clinical stages than the amplification group. Notably, all cases in the amplification group had latency type II, while 6/8 (75%) in the copy gain group had latency type II, and 2/8 (25%) had latency type I. Thus, a subset of the copy-gain group demonstrated more extensive extranodal lesions and higher clinical stages. This finding speculates the presence of a genetically distinct subgroup within the group of patients who develop immune deficiencies and dysregulation-associated lymphoproliferative disorders, which may explain certain characteristic features.
- 28 December 2022
- Published by Elsevier in The American Journal of Pathology
- Vol. 193 (3) , 350-361
Cancer Antigen 125 Expression Enhances the Gemcitabine/Cisplatin-Resistant Tumor Microenvironment in Bladder Cancer
- 28 December 2022
- Published by Elsevier in The American Journal of Pathology
- Vol. 193 (3) , 350-361
Cancer Antigen 125 Expression Enhances the Gemcitabine/Cisplatin-Resistant Tumor Microenvironment in Bladder Cancer